Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Subscribe To Our Newsletter & Stay Updated
